Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research

Journal of Surgical Oncology

Volumn 103, Issue 8, 2011, Pages 822-831

  Baratti, Dario ^a   Kusamura, Shigeki ^a   Deraco, Marcello ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

EGFR; hyperthermic intraperitoneal chemotherapy (HIPEC); peritonectomy; receptor tyrosine kinase; telomerase

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PEMETREXED;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CYTOREDUCTIVE SURGERY; HUMAN; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MESOTHELIOMA; NEOPLASM PROTEINS; PERITONEAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TELOMERASE;

EID: 79955696363     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21787     Document Type: Review

References (86)

1. Robinson BWS, Lake RA,: Advanced in malignant mesothelioma. New Eng J Med 2005; 353: 1591-1603.
2. Tsao AS, Wistuba I, Roth JA, et al.: Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-2090.
3. Price B, Ware A,: Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009; 39: 576-588.
4. de Pangher Manzini V, Recchia L, Cafferata M, et al.: Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010; 21: 348-353.
5. Sugarbaker PH, Welch LS, Mohamed F, et al.: A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12: 605-621. (Pubitemid 36920088)
6. Husain AN, Colby TV, Ordõñez NG, et al.: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331.
7. Cerruto CA, Brun EA, Chang D, et al.: Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 2006; 130: 1654-1661. (Pubitemid 44683793)
8. Rogoff EE, Hilaris B, Huvos AG,: Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 1973; 32: 656-664.
9. Jones DEC, Silver D,: Peritoneal mesothelioma. Surgery 1979; 86: 556-560.
10. Chahinian AP, Pajak TF, Holland JF, et al.: Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746-755. (Pubitemid 12029343)
11. Antman KH, Osteen R, Klegar K, et al.: Early peritoneal mesothelioma: a treatable malignancy. Lancet 1985; 2: 977-981. (Pubitemid 16215444)
12. Kirmani S, Cleary SM, Mowry J, et al.: Intracavitary cisplatin for malignant mesothelioma: an update. Proc Am Clin Oncol 1988; 7: (Abstract 1057).
13. van Gelder T, Hoogsteden HC, Versnel MA, et al.: Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989; 43: 222-227. (Pubitemid 20000300)
14. Markman M, Kelsen D,: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118: 547-550.
15. Neumann V, Muller KM, Fischer M,: Peritoneal mesothelioma-incidence and aetiology. Pathologe 1999; 20: 169-176.
16. Eltabbakh GH, Piver MS, Hempling RE, et al.: Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70: 6-12. (Pubitemid 29061988)
17. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644. (Pubitemid 46606305)
18. Garcia Carbonero R, Paz-Ares L,: Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32: 676-681. (Pubitemid 44063996)
19. Hassan R, Alexander R, Antman K, et al.: Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006; 17: 1615-1619. (Pubitemid 44680879)
20. Sugarbaker PH,: Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
21. NHS Centre for Reviews and Dissemination: Undertaking Systemic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews - CRD Report 4 (ed 2). York, United Kingdom, NHS Centre for Reviews and Dissemination, 2001
22. Blackham AU, Shen P, Stewart JH, et al.: Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 2010; 17: 1720-1727.
23. Feldman AL, Libutti SK, Pingpank JF, et al.: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560-4567. (Pubitemid 46594027)
24. Costamagna D, Scuderi S, Vaira M, et al.: Trattamento del mesotelioma peritoneale mediante citoriduzione e chemioipertermia intraperitoneale (CIIP). Tumori 2003; 89: 40-42.
25. Kluger MD, Taub RN, Hesdorffer M, et al.: Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol 2010; 36: 997-1003.
26. Yan TD, Brun EA, Cerruto CA, et al.: Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007; 14: 41-49. (Pubitemid 44954269)
27. Gõmez Portilla A, Cendoya I, Muriel J, et al.: Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia. Cir Esp 2007; 81: 82-86.
28. Elias D, Bedard V, Bouzid T, et al.: Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol 2007; 31: 784-788. (Pubitemid 350261618)
29. Passot G, Cotte E, Brigand C, et al.: Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. J Chir (Paris) 2008; 145: 447-453.
30. Foster JM, Gatalica Z, Lilleberg S, et al.: Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol 2009; 16: 152-158.
31. Chua TC, Yan TD, Morris DL,: Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 2009; 99: 109-113.
32. Yano H, Moran BJ, Cecil TD, et al.: Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol 2010; 35: 980-985.
33. Baratti D, Kusamura S, Cabras AD, et al.: Lymph-node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010; 17: 45-53.
34. Deraco M, De Simone M, Rossi CR, et al.: An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res 2003; 22: 41-45. (Pubitemid 38436432)
35. Yan TD, Deraco M, Baratti D, et al.: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma - a multi-institutional registry study. J Clin Oncol 2009; 27: 6237-6242.
36. Yan TD, Edwards G, Alderman R, et al.: Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma - a prospective study of 70 consecutive cases. Ann Surg Oncol 2007; 14: 515-525. (Pubitemid 46175296)
37. Yan TD, Welch L, Black D, et al.: A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007; 18: 827-834. (Pubitemid 47054078)
38. Borczuk AC, Taub RN, Hesdorffer M, et al.: P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005; 11: 3303-3308. (Pubitemid 40627879)
39. Simon GR, Verschraegen CF, Jänne PA, et al.: Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008; 26: 3567-3572.
40. Le DT, Deavers M, Hunt K, et al.: Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest 2003; 21: 682-689. (Pubitemid 37377322)
41. Janne PA, Wozniak AJ, Belani CP, et al.: Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005; 7: 40-46. (Pubitemid 41150472)
42. Carteni G, Manegold C, Garcia GM, et al.: Malignant peritoneal mesothelioma-results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009; 64: 211-218.
43. Lainakis G, Zagouri F, Kastritis E, et al.: Systemic chemotherapy with pemetrexed and cisplatin for malignant mesothelioma: a single institution experience. Tumori (in press).
44. Shay JW, Zou Y, Hiyama E, et al.: Telomerase and cancer. Hum Mol Genet 2001; 10: 677-685. (Pubitemid 32331575)
45. Henson JD, Hannay JA, McCarthy SW, et al.: A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005; 11: 217-225. (Pubitemid 40075798)
46. Villa R, Daidone MG, Motta R, et al.: Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2008; 14: 4134-4140.
47. Kim NW, Piatyszek MA, Prowse KR, et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
48. Trupiano JK, Geisinger KR, Willingham MC, et al.: Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004; 17: 476-481. (Pubitemid 41646604)
49. Nonaka D, Kusamura S, Baratti D, et al.: Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 2005; 104: 2181-2188. (Pubitemid 41579965)
50. Rocco JW, Sidransky D,: p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42-55. (Pubitemid 32989080)
51. Cheng JQ, Jhanwar SC, Klein WM, et al.: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5551.
52. Fennell DA, Rudd RM,: Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004; 5: 354-362. (Pubitemid 38684407)
53. Zaffaroni N, Costa A, Pennati M, et al.: Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 2007; 29: 453-466. (Pubitemid 350136500)
54. Salvesen GS, Duckett CS,: IAP proteins: blocking the road to death's door. Nature Rev Mol Cell Biol 2002; 3: 401-410. (Pubitemid 34685698)
55. Du C, Fang M, Li Y, et al.: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
56. Altieri DC,: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54. (Pubitemid 37328886)
57. Borczuk AC, Cappellini GC, Kim HK, et al.: Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 2007; 26: 610-617. (Pubitemid 46160974)
58. Rajkumar SV, Richardson PG, Hideshima T, et al.: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639. (Pubitemid 46224241)
59. Robinson BW, Creaney J, Lake R, et al.: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616. (Pubitemid 37443528)
60. Bast RC, Klug TL, St John E, et al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med 1983; 309: 883-887. (Pubitemid 13014028)
61. Rump A, Morikawa Y, Tanaka M, et al.: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004; 279: 9190-9198. (Pubitemid 38295982)
62. Kaneko O, Gong L, Zhang J, et al.: A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009; 284: 3739-3749.
63. Hassan R, Schweizer C, Lu KF, et al.: Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer 2010; 68: 455-459.
64. Kreitman RJ, Hassan R, Fitzgerald DJ, et al.: Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15: 5274-5279.
65. Govindan R, Kratzke RA, Herndon JE II, et al.: Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia Group B. Clin Cancer Res 2005; 11: 2300-2304. (Pubitemid 40490190)
66. Garland LL, Rankin C, Gandara DR, et al.: Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007; 25: 2406-2413. (Pubitemid 46999211)
67. Mathy A, Baas P, Dalesio O, et al.: Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50: 83-86. (Pubitemid 41297473)
68. Porta C, Mutti L, Tassi G, et al.: Negative results of an Italian Group for Mesothelioma (G.I. Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007; 59: 149-150. (Pubitemid 44796113)
69. Perrone F, Jocollà G, Brich S, et al.: Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer 2010; 46: 2837-2848.
70. Loggie BW, Fleming RA, McQuellon RP, et al.: Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67: 999-1003. (Pubitemid 33738134)
71. Park BJ, Alexander HR, Libutti SK, et al.: Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6: 582-590. (Pubitemid 29428799)
72. Sebbag G, Yan H, Shmookler BM, et al.: Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87: 1587-1593.
73. Chua TC, Yan TD, Saxena A, et al.: Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 2009; 249: 900-907.
74. Smeenk RM, Verwaal VJ, Zoetmulder FAN,: Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 2007; 94: 1408-1414. (Pubitemid 350144391)
75. Langer CJ, Rosenblum N, Hogan M, et al.: Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993; 32: 204-208. (Pubitemid 23146813)
76. Lederman GS, Recht A, Herman T, et al.: Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer 1987; 59: 1882-1886. (Pubitemid 17072412)
77. Sticca RP, Dach BW,: Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003; 12: 689-701. (Pubitemid 36920093)
78. Los G, Smals OA, van Vugt MJ, et al.: A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992; 52: 1252-1258.
79. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al.: Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34: 148-154. (Pubitemid 28123393)
80. Barlogie B, Corry PM, Drewinko B,: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980; 40: 1165-1181.
81. Yan TD, Haveric N, Carmignani CP, et al.: Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005; 103: 839-849. (Pubitemid 40216414)
82. Los G, Mutsaers PH, Lenglet WJ, et al.: Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990; 25: 389-394. (Pubitemid 20069336)
83. Deraco M, Bartlett D, Kusamura S, et al.: Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008; 98: 268-272.
84. Montgomery E, Argani P, Hicks JL, et al.: Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004; 164: 1523-1529. (Pubitemid 38529754)
85. Harley CB,: Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8: 167-179. (Pubitemid 351305939)
86. Goldblatt EM, Gentry ER, Fox MJ, et al.: The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther 2009; 8: 2027-2035.